ASCO® 2024 Insights: "Young-PEARL Study - Palbociclib + Exemestane With GnRH Agonist vs. Capecitabine in Premenopausal Patients With HR+/HER2- mBC" | VuMedi

Find latest Breast Cancer videos · 1000+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Young-PEARL Study - Palbociclib + Exemestane With GnRH Agonist vs. Capecitabine in Premenopausal Patients With HR+/HER2- mBC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Yeon Hee Park

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Yeon Hee Park

269 views

July 10, 2024

Comments 0

Login to view comments. Click here to Login